Paratek Pharmaceuticals (NASDAQ:PRTK) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Friday.
Several other equities research analysts have also issued reports on the stock. Bank of America started coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They issued a “neutral” rating and a $13.00 price objective for the company. ValuEngine raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush set a $20.00 price objective on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, Guggenheim set a $26.00 price objective on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.50.
NASDAQ:PRTK opened at $9.32 on Friday. The company has a current ratio of 7.88, a quick ratio of 7.88 and a debt-to-equity ratio of 2.37. The company has a market cap of $307.78 million, a price-to-earnings ratio of -2.82 and a beta of 0.57. Paratek Pharmaceuticals has a fifty-two week low of $8.69 and a fifty-two week high of $24.70.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, equities analysts predict that Paratek Pharmaceuticals will post -3.41 earnings per share for the current fiscal year.
In related news, VP Adam Woodrow sold 8,750 shares of the firm’s stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total transaction of $85,925.00. Following the completion of the sale, the vice president now directly owns 112,917 shares of the company’s stock, valued at approximately $1,108,844.94. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Michael Bigham sold 16,313 shares of the firm’s stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total transaction of $160,193.66. Following the sale, the chairman now directly owns 213,480 shares of the company’s stock, valued at $2,096,373.60. The disclosure for this sale can be found here. Insiders sold 41,503 shares of company stock valued at $407,559 in the last three months. Company insiders own 6.20% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Balter Liquid Alternatives LLC acquired a new stake in Paratek Pharmaceuticals during the 2nd quarter valued at $137,000. Cubist Systematic Strategies LLC acquired a new stake in Paratek Pharmaceuticals during the 1st quarter valued at $147,000. Metropolitan Life Insurance Co. NY grew its holdings in Paratek Pharmaceuticals by 81.4% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 6,625 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Paratek Pharmaceuticals during the 2nd quarter valued at $154,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Paratek Pharmaceuticals during the 1st quarter valued at $162,000. 77.31% of the stock is owned by institutional investors and hedge funds.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.